Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors
- 27 September 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (22), 6307-6312
- https://doi.org/10.1016/j.bmcl.2009.09.096
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Discovery of a Potent, Selective, and Orally Bioavailable c-Met Inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Journal of Medicinal Chemistry, 2008
- Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met KinaseJournal of Medicinal Chemistry, 2008
- An Examination of IC50 and IC50-Shift Experiments in Assessing Time-Dependent Inhibition of CYP3A4, CYP2D6 and CYP2C9 in Human Liver MicrosomesDrug Metabolism Letters, 2008
- Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applicationsExpert Opinion on Therapeutic Patents, 2007
- Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic DrugsClinical Pharmacokinetics, 2005
- Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4Therapeutics and Clinical Risk Management, 2005
- Hereditary Papillary Renal Carcinoma Type ICurrent Molecular Medicine, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal modelsProceedings of the National Academy of Sciences, 2001
- Tyrosine kinase receptor indistinguishable from the c-met proteinNature, 1989